Veozah is an oral neurokinin 3 (NK3) receptor antagonist.
A decision on the OTC oral contraceptive pill is expected later this year.
The safety and efficacy of fezolinetant in the treatment of menopause-related vasomotor symptoms were assessed.
Interrupting adjuvant endocrine therapy to attempt pregnancy does not increase the risk of breast cancer recurrence, a study suggests.
Treatment with Prolia was associated with greater reductions in the overall relative risk across various fracture types.
Researchers sought to determine the extent in which sex, age at menopause, and hormone therapy use are associated with regional tau at a given level of Aβ — both measured with PET.
Investigators searched publication databases from inception through to July 2021 for studies about loneliness in the perinatal setting for this meta-synthesis.
If approved, Opill would be the first daily oral contraceptive pill available without a prescription.
Researchers studied the link between plant-based dietary patterns and osteoporosis among older adults.
In an international meta-analysis, researchers evaluated sex differences in all-cause dementia risk across diverse ethno-regional groups.
Researchers evaluated the effectiveness and safety of COVID-19 vaccination during pregnancy.
Researchers sought to assess the role of APOE genotype and age at HRT initiation on the heterogeneity in cognitive response to HRT.
Researchers evaluated changes in menstruation following COVID-19 vaccination.
Emzahh is an AB-rated generic equivalent of Ortho Micronor.
Experts discuss strategies to reduce the maternal mortality gap by implementing implicit bias training and reevaluating clinical guidelines and algorithms.
Mifepristone is a progestin antagonist indicated, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation.
ACOG experts provide actionable steps to reduce the maternal mortality crisis in the US, particularly among minority populations.
Researchers sought to investigate whether health care providers investigated heavy menstrual bleeding as a potential symptom of an underlying bleeding disorder.
Brexafemme is an oral antifungal agent representing a novel therapeutic class of structurally-distinct glucan synthase inhibitors known as triterpenoids.
Researchers sought to determine whether there was a link between abnormal menstrual bleeding and treatment with anticoagulants for VTE.